Importance

Loading Importance Indicators...

Abstract

The invention relates to compounds of the formula (I) R.sup.1 --Q.sup.1 --X--Q.sup.2 --R.sup.2, in which: Q.sup.1, Q.sup.2, each independent of one another, are missing or are --NH--(CH.sub.2).sub.n --CO--; R.sup.1, R.sup.2, each independent of one another, are missing or are cyclo-(Arg-Gly-Asp-Z), wherein Z is missing in side chain of Q.sup.1 or Q.sup.2 of if Q.sup.1 and/or Q.sup.2 missing, is bound to X, at least one of the groups R.sup.1 or R.sup.2 always having to be included; X is --CO--R.sup.18 --CO--, and if R.sup.1 --Q.sup.1 -- or R.sup.2 --Q.sup.2 --are missing is R.sup.10, R.sup.13, Het-CO or a flourescent pigment residue linked through a --CONH--, --COO--, NH--C(.dbd.S)--N--, --NH--C(.dbd.O)--NH--, --SO.sub.2 NH--or --NHCO-- bond; and Z, R.sup.10, R.sup.13, R.sup.16, R.sup.18, Het and n have the meaning given in claim 1. The invention also relates to the salts of said compounds. These compounds and their salts can be used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy.

Loading the Abstract Image...

First Claim